"所以华得森生物现在选择做多平台同时研发，包含目前国内循环肿瘤细胞检测的主流方法学。我们对 多种方法学进行解构、重组，希望制造出对于这个检测来说最优的方法学选择。"赵丹说道："目前我们 已与国内近30家百强头部医院达成合作，从整体临床使用端数据来看，已经明确了产品的合规性和临床 有效性，建立了坚实的行业壁垒。" 而对于行业未来发展，赵丹说道："现在不管是肿瘤药物还是临检行业，都希望通过实时动态监测、及 时的个性化治疗延长患者的生存期，以期把肿瘤发展成慢性病，而不再是一谈到肿瘤就联想到死亡。" 华得森的主营业务是液体活检----循环肿瘤细胞检测。赵丹指出，通过循环肿瘤细胞检测，可以做到对 肿瘤的早期辅助诊断、预后评估、疗效评价和疾病进展监测等，是整体肿瘤诊疗过程的全程管理工具。 华得森生物是目前国内第一家从设备到检测试剂均获得国家三类注册认证的企业。赵丹说到，国内液体 活检行业已发展数十年，很多企业在没有取得注册认证，没有明确临床应用场景的情况下就已开展临床 检测，缺乏产品合规性和临床数据有效性支撑。 他进一步指出，目前循环肿瘤细胞检测行业仍缺乏国家的参考标准，而各厂家产品之间的数据缺乏一致 性。同一种检测，使 ...

Group 1 - Mirxes Holding Limited, a leading cancer early screening company in Singapore, was listed on the Hong Kong Stock Exchange on May 23, 2025, and was included in the Hang Seng Composite Index and Hong Kong Stock Connect within four months, indicating strong international market recognition [1] - For the first half of 2025, Mirxes reported revenue of $10.5 million, a 9.4% increase compared to the same period in 2024, with gross profit reaching $7.1 million, up 51.1%, and gross margin significantly improving from 49.0% to 67.6% [1] - The company's loss decreased by 36.3% year-on-year to $28.23 million, reflecting improved financial performance [1] Group 2 - Mirxes was founded in 2014 and is a global leader in RNA liquid biopsy, focusing on the research of blood cfRNA and cfDNA, while integrating information from proteins, imaging, and epidemiology through multi-dimensional machine learning models [1] - The company has developed its proprietary mSMRT-qPCR technology platform and has conducted multiple studies in early screening for gastric, lung, and breast cancers, with research published in international journals such as Gut, PNAS, and Cancers [1] - In 2020, Mirxes initiated the first national standard for microRNA diagnostics in Singapore, collaborating with prestigious institutions, and is set to be included in the ISO certification system [2] - The company launched the world's first serum gastric cancer molecular diagnostic kit, GASTRO ClearTM, in Singapore in 2019 and was recognized by Nature Biotechnology as the only Asian company on the "Global Liquid Biopsy Innovation Companies" list [2]